Patents by Inventor Hidde Ploegh

Hidde Ploegh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200155660
    Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
    Type: Application
    Filed: November 22, 2019
    Publication date: May 21, 2020
    Inventors: Omar F. Khan, Jasdave S. Chahal, Daniel G. Anderson, Hidde Ploegh, Robert S. Langer, Tyler E. Jacks, David A. Canner
  • Patent number: 10548959
    Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: February 4, 2020
    Assignees: Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research
    Inventors: Omar F. Khan, Jasdave S. Chahal, Daniel G. Anderson, Hidde Ploegh, Robert S. Langer, Tyler E. Jacks, David A. Canner
  • Patent number: 9751945
    Abstract: In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: September 5, 2017
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Hidde Ploegh, Maximilian Popp, Juanjo Cragnolini
  • Publication number: 20170079916
    Abstract: Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 23, 2017
    Inventors: Omar F. Khan, Jasdave S. Chahal, Daniel G. Anderson, Hidde Ploegh, Robert S. Langer
  • Publication number: 20150086576
    Abstract: In some aspects, polypeptides comprising single domain antibodies and methods of identifying single domain antibodies are provided. In some embodiments polypeptides comprising a single domain antibody and a sortase recognition sequence, are provided. In some aspects, products and methods of use in modulating the immune system, e.g., modulating an immune response, are provided.
    Type: Application
    Filed: April 15, 2013
    Publication date: March 26, 2015
    Inventors: Hidde Ploegh, Maximilian Popp, Juanjo Cragnolini
  • Publication number: 20130122043
    Abstract: The present invention provides modified multi-chain and multi-subunit proteins and methods for making them. In some protease embodiments the proteins are modified AB5 toxins in which a compound of interest is attached to the A1 chain.
    Type: Application
    Filed: April 20, 2011
    Publication date: May 16, 2013
    Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Carla Guimaraes, Hidde Ploegh
  • Publication number: 20110302665
    Abstract: The present invention provides non-human mammals, e.g., mice, generated from a T cell or B cell with a predefined specificity or isolated from an organism suffering from a condition of interest. In some embodiments the non-human mammals are not genetically modified. Also provided are methods of using the non-human animals.
    Type: Application
    Filed: July 2, 2009
    Publication date: December 8, 2011
    Inventors: Oktay Kirak, Gijsbert M. Grotenbreg, Eva-Maria Frickel, Rudolf Jaenisch, Hidde Ploegh
  • Publication number: 20070092942
    Abstract: Disclosed is a new class of deubiquitinating enzymes that are conserved across the family Herpesviridae.
    Type: Application
    Filed: August 18, 2006
    Publication date: April 26, 2007
    Inventors: Gregory Korbel, Hidde Ploegh, Lisa Kattenhorn, Christian Schlieker
  • Publication number: 20050277762
    Abstract: A C-terminally modified Ubiquitin (Ub) derivative) ubiquitin vinyl sulfone (UbVS), which is specific for deubiquitinating enzymes (DUBs), was synthesized as an active site directed probe that irreversibly modifies a subset of Ub C-terminal hydrolases (UCHs) and Ub specific processing proteases (UBPs), is provided. [125I]-UbVS modifies 6 of the 17 known and putative yeast deubiquitinating enzymes, namely Yuh1p, Ubp1p, Ubp2p, Ubp6p, Ubp12p and Ubp15p. In mammalian cells, a greater number of polypeptides is labeled, most of which are DUBs. An additional DUB that associates with the mammalian 26S proteasome, novel protein USP14, a mammalian homolog of yeast Ubp6p that is bound to the proteasome, is provided.
    Type: Application
    Filed: April 25, 2003
    Publication date: December 15, 2005
    Inventors: Hidde Ploegh, Huib Ovaa, Anna Borodovsky, Benedikt Kessler, Joris Hemelaar, Paul Galardy, Nagamalleswari Kolli, Tudevin Gan-Erdene, Keith Wilkinson
  • Publication number: 20050095248
    Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide based inhibitors of cathepsin S are also described.
    Type: Application
    Filed: August 5, 2004
    Publication date: May 5, 2005
    Applicants: Massachusetts Institute of Technology, Brigham and Women's Hospital
    Inventors: Hidde Ploegh, Harold Chapman, Richard Riese, Paula Bryant, Matthew Bogyo
  • Publication number: 20050080010
    Abstract: Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide based inhibitors of cathepsin S are also described.
    Type: Application
    Filed: August 14, 2003
    Publication date: April 14, 2005
    Inventors: Hidde Ploegh, Harold Chapman, Richard Riese, Paula Bryant, Matthew Bogyo